Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
No takes yet. Share an insight, caveat, or question.
Frías et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: